Cynapsus Therapeutics Inc. (CYNA)

[Seel]

From Nov 15 presentation:

Anticipated Upcoming Milestones and Estimated Timeline
• December 2015 - Posters and symposium sponsorship at the XXI World Congress
on Parkinson’s Disease and Related Disorders in Milan, Italy
• Q4 2015 - Completion of CTH-200 bridging study
• Q4 2015 - Update on initial regulatory and clinical activities for European market
registration
• Q2 2016 - Top-line data from CTH-300 Phase 3 efficacy registration study
• Q4 2016 - Top-line data from CTH-301 Phase 3 safety registration study
• Q4 2016 - File New Drug Application with U.S. FDA

20
Financial Position*
Cash • CAD$109.5 million (USD $82.2 million)
• 12,144,622 common shares
• 3,260,954 warrants
• 973,017 options
• 16,348,593 Total (Fully Diluted)
Share Capital
*As at September 30, 2015
Cash numbers include USD$72.5 million public offering (less expenses) of 5,175,000 common shares
in the United States, which closed on June 23, 2015.
Stock symbols: NASDAQ (CYNA), TSX (CTH)